Bone Growth Stimulator Market Report 2026

Bone Growth Stimulator Market Overview

• Bone Growth Stimulator market size has reached to $1.8 billion in 2025 • Expected to grow to $2.89 billion in 2030 at a compound annual growth rate (CAGR) of 9.8% • Growth Driver: Fueling Market Expansion The Role Of Increasing Bone Fractures In The Growth Of The Bone Growth Stimulators Market • Market Trend: Portable Low-Intensity Pulsed Ultrasound Bone Growth Stimulator To Enhance Fracture Healing • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Bone Growth Stimulator Market?

The bone growth stimulator is an electrical osteogenesis stimulator used to boost the natural fusion of bone after a fracture. The purpose of BGS is to send more energy to the healing bone surface through either pulsed electromagnetic or ultrasound. The electromagnetic field allows attracting the two oppositely charged ends of the bones to each other by stimulating new bone growth and fusion, which leads to healing. The bone growth stimulator is used to boost bone healing for difficult to heal fractures or fusions through applying ultrasonic or electrical current to the fracture/fusion site. The main type of bone growth stimulators (BGS) are bone growth stimulation devices, bone morphogenetic proteins (BMP) and platelet-rich plasma (PRP) therapy. The bone growth stimulation devices are implanted internally or can be worn on the outside of the body using straps to secure them in place to improve fracture healing rate and shorten fracture healing time. These BGS can be implantable device and external device and have application in the treatment of fractures, spinal fusion, osteogenesis, arthrodesis treatment and spondylolithesis. The major end use sectors of BGS are hospitals & ASCs, specialty clinics, and home care.

What Is The Bone Growth Stimulator Market Growth Forecast?

The bone growth stimulator market size is expected to see strong growth in the next few years. It will grow to $2.89 billion in 2030 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to increasing demand for home-based orthopedic therapies, rising adoption of smart medical devices, expansion of outpatient orthopedic care, growing focus on reducing surgical interventions, technological advancements in bioelectrical stimulation. Major trends in the forecast period include increasing adoption of non-invasive bone growth stimulators, rising use of ultrasound-based stimulation devices, growing integration of smart monitoring features, expansion of home-use bone healing solutions, enhanced focus on faster fracture recovery.

Global Bone Growth Stimulator Market Segmentation

1) By Type: Electrical Bone Growth Stimulators, Ultrasound Bone Growth Stimulators, Pulsed Electromagnetic Field (PEMF) Bone Growth Stimulators 2) By Application: Fractures, Spinal Fusion, Osteogenesis, Arthrodesis Treatment 3) By End User: Hospitals & ASCs, Specialty Clinics, Home Care Subsegments: 1) By Electrical Bone Growth Stimulators: Implantable Electrical Bone Growth Stimulators, Non-Invasive (External) Electrical Bone Growth Stimulators, Direct Current (DC) Bone Growth Stimulators, Capacitive Coupling Bone Growth Stimulators 2) By Ultrasound Bone Growth Stimulators: Low-Intensity Pulsed Ultrasound (LIPUS) Bone Growth Stimulators, External Ultrasound Bone Growth Stimulators, Portable Or Wearable Ultrasound Bone Growth Stimulators 3) By Pulsed Electromagnetic Field (PEMF) Bone Growth Stimulators: Non-Invasive PEMF Bone Growth Stimulators, Implantable PEMF Bone Growth Stimulators, Portable PEMF Bone Growth Stimulators, Wearable PEMF Bone Growth Stimulators

What Is The Driver Of The Bone Growth Stimulator Market?

The rising number of bone fractures is expected to significantly drive the growth of the bone growth stimulators market. A person's bones typically weaken with age, dietary habits, and other chronic disorders. The overuse of repetitive motions can tire muscles and put more pressure on the bones, leading to bone fracture. For instance, in June 2025, according to PubMed, the US-based National Institutes of Health reported that, in China, projected data suggests that the ASIR for radius and/or ulna fractures in males will rise from 369 per 100,000 to 374 per 100,000 from 2022 to 2029. Further, the rate in females is expected to steadily increase from 427 per 100,000 in 2022 to 502 per 100,000 in 2036. Therefore, the rise in the number of bone fractures is expected to drive the growth of the bone growth stimulator industry.

Key Players In The Global Bone Growth Stimulator Market

Major companies operating in the bone growth stimulator market are Bioventus LLC, Orthofix Medical Inc., Zimmer Biomet Holdings Inc., Medtronic plc, Enovis Inc., ZimVie Inc., DJO Global Inc., Smith & Nephew plc, Stryker Corporation, DePuy Synthes Inc., Globus Medical Inc., NuVasive Inc., Exactech Inc., Wright Medical Group N.V., RTI Surgical Holdings Inc., Ossatec Benelux BV, BTT Health GmbH, Stimulate Health Inc., Arthrex Inc., ConMed Corporation, Integra LifeSciences Corporation, OrthoPediatrics Corp.

Global Bone Growth Stimulator Market Trends and Insights

Major companies are operating in the bone growth stimulator market, focusing on developing technological advancements such as low-intensity pulsed ultrasound (LIPUS) devices for non-invasive bone healing to enhance fracture repair, improve patient compliance, and reduce recovery time. A LIPUS device uses low-power ultrasonic waves to stimulate osteoblast activity at the fracture site, promoting faster bone regeneration compared to traditional electrical or implantable stimulators. For instance, in July 2025, Enovis Corporation, a U.S.-based medical technology company, launched the Manafuse Bone Growth Stimulator. The product delivers daily 20-minute LIPUS therapy sessions through a lightweight, portable device with built-in compliance tracking, offering faster fracture healing, up to 38% quicker in acute fractures and improved patient usability compared to previous bulky or implant-based systems.

What Are Latest Mergers And Acquisitions In The Bone Growth Stimulator Market?

In June 2025, Avista Healthcare Partners, a US-based private equity firm, acquired EBI, LLC for an undisclosed amount. Through this acquisition, Avista aims to strengthen its presence in the bone growth stimulator market by leveraging EBI’s portfolio of implantable and non-invasive bone growth stimulation devices for fracture healing and spinal fusion. EBI, LLC is a US-based medical technology company that provides both implantable and non-invasive bone growth stimulation solutions, including OsteoGen, OrthoPak, and SpinalPak.

Regional Outlook

North America was the largest region in the bone growth stimulator market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Bone Growth Stimulator Market?

The bone growth stimulator market consists of sales of electrical and ultrasound bone growth stimulator. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.